Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Shan Dong Kexing Bioproducts Co's Debt-to-Equity or its related term are showing as below:
SHSE:688136'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.14 Med: 0.6 Max: 0.82
Current: 0.79
During the past 9 years, the highest Debt-to-Equity Ratio of Shan Dong Kexing Bioproducts Co was 0.82. The lowest was 0.14. And the median was 0.60.
SHSE:688136's Debt-to-Equity is ranked worse than 83.54% of 966
companies
in the Biotechnology industry
Industry Median: 0.15
vs SHSE:688136: 0.79
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Shan Dong Kexing Bioproducts Co Debt-to-Equity Related Terms
Shan Dong Kexing Bioproducts Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shan Dong Kexing Bioproducts Co Debt-to-Equity Chart
SHSE:688136 vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Shan Dong Kexing Bioproducts Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shan Dong Kexing Bioproducts Co Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shan Dong Kexing Bioproducts Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Shan Dong Kexing Bioproducts Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shan Dong Kexing Bioproducts Co (SHSE:688136) has a Debt-to-Equity of 0.79 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Shan Dong Kexing Bioproducts Co and its competitors. This is 32% above median its historical median of 0.60. Over the past decade, Shan Dong Kexing Bioproducts Co's Debt-to-Equity has ranged from 0.14 to 0.82. According to the industry distribution chart, Shan Dong Kexing Bioproducts Co ranks #807 out of 966 companies in the Biotechnology industry, placing it in the top 83.5%.
Is Shan Dong Kexing Bioproducts Co's Debt-to-Equity too high?
Shan Dong Kexing Bioproducts Co's current Debt-to-Equity of 0.79 is 32% above median its 10-year median of 0.60. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 0.82. The Biotechnology industry median Debt-to-Equity is 0.15. Shan Dong Kexing Bioproducts Co's value of 0.79 is 426.7% above this industry median. Based on the distribution chart, Shan Dong Kexing Bioproducts Co ranks #807 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shan Dong Kexing Bioproducts Co has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shan Dong Kexing Bioproducts Co's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shan Dong Kexing Bioproducts Co ranks #807 out of 966 companies for Debt-to-Equity. This places Shan Dong Kexing Bioproducts Co in the lower half of its industry. The industry median Debt-to-Equity is 0.15. Shan Dong Kexing Bioproducts Co's value of 0.79 is 426.7% above this benchmark. Historically, Shan Dong Kexing Bioproducts Co's own Debt-to-Equity has ranged from 0.14 to 0.82 over the past decade. While the company's 10-year median is 0.60 vs. the industry median of 0.15, Shan Dong Kexing Bioproducts Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shan Dong Kexing Bioproducts Co's current Debt-to-Equity of 0.79 is 426.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Shan Dong Kexing Bioproducts Co and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shan Dong Kexing Bioproducts Co's current Debt-to-Equity is 0.79, which is 32% above median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shan Dong Kexing Bioproducts Co stock overvalued right now?
Based on GuruFocus' analysis, Shan Dong Kexing Bioproducts Co (SHSE:688136) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥23.47, compared to a current price of ¥19.62 — trading 16.4% below its estimated fair value. The current Debt-to-Equity is 0.79, which is 32% above median its 10-year median of 0.60 and 426.7% above the Biotechnology industry median of 0.15. Shan Dong Kexing Bioproducts Co's overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Shan Dong Kexing Bioproducts Co (SHSE:688136), the current Debt-to-Equity is 0.79 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shan Dong Kexing Bioproducts Co (SHSE:688136) Overvalued in 2026?
Based on GuruFocus' analysis, Shan Dong Kexing Bioproducts Co stock appears to be undervalued.
The current stock price of ¥19.62 is trading 16.4% below its estimated GF Value™ of ¥23.47.
GuruFocus considers Shan Dong Kexing Bioproducts Co to be Modestly Undervalued.
Key valuation signals for SHSE:688136:
Debt-to-Equity: 0.79 (32% above median its 10-year median of 0.60)
GF Value™: ¥23.47 vs. price of ¥19.62 (16.4% below fair value)
Industry Position: 426.7% above the Biotechnology median (#807 of 966)
No single metric tells the full story. See the SHSE:688136 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shan Dong Kexing Bioproducts Co Ltd formerly Kexing Biopharmaceutical Co Ltd is an innovative biopharmaceutical company. It is engaged in the production and sales of recombinant protein drugs and probiotics. The company use the drugs in the fields of antiviral, hematology, tumor and immunity, and degenerative diseases.
45GF Score
Get the complete analysis for SHSE:688136
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688136 has been successfully added to your 
